NetworkNewsBreaks – ContraFect Corp. (NASDAQ: CFRX) Featured in Mizuho Securities Research Report
ContraFect (NASDAQ: CFRX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “ContraFect reported 2Q 2020 results and provided an update on their clinical program on Friday. We also had a chance to catch up with the company directly following the release. Most importantly, things appear to be on track for lead asset exebacase and the ongoing Phase 3 DISRUPT trial. While the COVID-19 pandemic may naturally impact the progress of the trial, they continue to expect interim data (after 60% enrollment) in 1H 2021 and final results in 2H 2021. We…







